Companies: 10,795·Total market cap: $144.5T
Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock

RAPPNASDAQHealthcare● Active
$36.42
+$0.32(+0.89%)
Market Cap$1.3B
P/E Ratio
52W High$42.269
52W Low$10.505
SEC Filings

Rapport Therapeutics, Inc. Common Stock (RAPP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0002012593 · RAPP · NASDAQ · as of Jun 8, 2026

Filing snapshot

198
Total Filings
4
Latest Form
2026-05-28
Most Recent
2024
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0002012593 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-10
Fiscal Year End
Mar 10, 2026
Accession No.
0001193125-26-099360
Primary Document
rapp-20251231.htm
Source: data.sec.gov · CIK 0002012593 · Accession 0001193125-26-099360

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
8-KCurrent Report
8-K
2026-04-21
View
S-3ASRS-3ASR
S-3ASR
2026-03-10
View
S-8Employee Stock Plan Registration
S-8
2026-03-10
View
10-KAnnual Report
10-K
2026-03-10
View
8-KCurrent Report
8-K
2026-03-10
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-01-21
View
8-KCurrent Report
8-K
2026-01-07
View
424B5424B5
424B5
2026-01-07
View
Showing 1–15 of 103 filingsForm 4 / 144 hidden· 198 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0002012593  |  Exchange: NASDAQ · Healthcare

Rapport Therapeutics, Inc. Common Stock (NASDAQ: RAPP) has submitted 198 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2024. As a Healthcare sector company with CIK 0002012593, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Rapport Therapeutics, Inc. Common Stock's most comprehensive regulatory disclosure. The most recent Rapport Therapeutics, Inc. Common Stock 10-K was filed on 2026-03-10 for fiscal year ending 2026. Historical RAPP 10-K annual reports are available from 2024 through 2026.

Investors researching Rapport Therapeutics, Inc. Common Stock SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

RAPP SEC Filings · 8 questions

Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 198 filings and access original documents at no cost. Rapport Therapeutics, Inc. Common Stock's CIK is 0002012593.

RAPP SEC filingsRapport Therapeutics, Inc. Common Stock SEC documentsfind RAPP 10-K